Article

STAAR Surgical introduces ICL delivery system, practice building program

STAAR Surgical Co. announced a certification course for refractive surgeons for the company's implantable collamer lens (Visian ICL). The company also launched a micro-incision delivery system (nanoPOINT), which can inject the single-piece IOL through a 2.2-mm incision compared with the current requirement of a 2.8- to 3-mm incision.

STAAR Surgical Co. announced a certification course for refractive surgeons for the company'simplantable collamer lens (Visian ICL). The company also launched a micro-incision deliverysystem (nanoPOINT), which can inject the single-piece IOL through a 2.2-mm incision comparedwith the current requirement of a 2.8- to 3-mm incision.

In addition, STAAR Surgical's aspheric foldable IOL (Afinity Collamer, Model CQ2015A) recentlyreceived designation as a New Technology Intraocular Lens.

The company also introduced a nine-part ICL growth program for refractive surgeons. The Webseminar/conference call program features Brian Boxer Wachler, MD, and focuses on the keyelements required to build a successful ICL practice. The program is designed to helpinterested surgeons capitalize on the growing consumer awareness of the lens' benefits andcontinue its recent progress in the U.S. market.

For more information, visit STAAR Surgical at booth 1228.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
© 2025 MJH Life Sciences

All rights reserved.